Drug Screening Using IMD in Bladder Cancer
Public ClinicalTrials.gov record NCT06204614. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Response in Primary Bladder Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This research study involves implanting up to 4 microdevices, each small enough to fit inside the tip of a needle, into a tumor. These devices will release microdoses (many thousands of times less than a treatment dose) of different cancer drugs into the tumor. After approximately 72 hours, the devices and small regions of surrounding tissue will be removed and studied. There will be a follow-up visit within 42 days of device removal to assess for potential safety issues or side effects.
Study identification
- NCT ID
- NCT06204614
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Early Phase 1
- Enrollment
- 18 participants
Conditions and interventions
Conditions
Interventions
- Implantable Micro-Device Device
- Methotrexate Drug
- Carboplatin Drug
- Avelumab Drug
- Paclitaxel Drug
- Vinblastine Drug
- Gemcitabine/Cisplatin I Drug
- Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab Drug
- Gemcitabine/Cisplatin II Drug
- Cisplatin Drug
- Nivolumab Drug
- Pembrolizumab Drug
- Gemcitabine/Carboplatin Drug
- Methotrexate/Vinblastine/Doxorubicin/Cisplatin Drug
- Gemcitabine/Cisplatin/Nivolumab Drug
- Erdafitinib Drug
- Paclitaxel/Docetaxel/Ifosfamide Drug
- Gemcitabine Drug
- Gemcitabine/Carboplatin/Nivolumab Drug
- Enfortumab Drug
- Sacituzumab Drug
Device · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 120 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 13, 2024
- Primary completion
- Jun 30, 2028
- Completion
- Jul 31, 2028
- Last update posted
- May 17, 2026
2024 – 2028
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06204614, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 17, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06204614 live on ClinicalTrials.gov.